Chrysalis BioTherapeutics, Inc. is a privately held biopharmaceutical development company working to save lives and improve life’s quality. The company is developing drugs that mimic the body’s natural regenerative signals to activate and protect endogenous endothelial progenitor cells and stem cells located within tissues to repair and regenerate tissues damaged by injury, disease, and radiation exposure.
Mitigating Effects of Radiation Exposure
The company is currently focused on developing drug products to mitigate effects of radiation exposure. Injection of the company’s lead product Chrysalin® 24 hours after nuclear exposure increases survival and accelerates wound healing in preclinical studies. Chrysalin® treatment also protects normal tissues from damaging effects of radiation therapy without affecting radiation killing of tumor cells.
Preclinical studies have shown that Chrysalin® reduces restenosis, protects heart muscle from effects of acute myocardial infarction, and helps to restore vascular perfusion and function to the left ventricle of hearts with chronic myocardial ischemia.
Tissue Repair and Regenerative Medicine
Clinical trials have shown potential efficacy of Chrysalin® in treating diabetic foot ulcers and distal radius fractures. These effects appear to be mediated by activation and recruitment of endogenous progenitor cells located within tissues bypassing the need for stem cell therapy. This unique mode of action suggests that Chrysalin® may have therapeutic benefit for a number of clinical indications.